WO2017066240A1 - Enhancing beta cell replication and/or survival - Google Patents
Enhancing beta cell replication and/or survival Download PDFInfo
- Publication number
- WO2017066240A1 WO2017066240A1 PCT/US2016/056528 US2016056528W WO2017066240A1 WO 2017066240 A1 WO2017066240 A1 WO 2017066240A1 US 2016056528 W US2016056528 W US 2016056528W WO 2017066240 A1 WO2017066240 A1 WO 2017066240A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- less
- pam
- gaba
- activating ligand
- receptor activating
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A61K31/515—Barbituric acids; Derivatives thereof, e.g. sodium pentobarbital
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Definitions
- Beta cells are a type of pancreatic cell located in the islets of
- the pancreas serves two major functions: (i) the production of digestive enzymes, that are secreted by exocrine acinar cells and routed to the intestine by a branched ductal network; and (ii) the regulation of blood sugar, which is achieved by endocrine cells of the islets of Langerhans. Several separate endocrine cell types comprise the islet.
- Pancreatic ⁇ cells also referred to as ⁇ -cells or "beta cells" are the most prominent representing about 50-80% of the total depending on species.
- B-cells produce a number of polypeptides including insulin, a hormone that controls the level of glucose in the blood, C- peptide, a byproduct of insulin production, that helps to prevent neuropathy and other symptoms of diabetes related to vascular deterioration, and amylin, also known as islet amyloid polypeptide (IAP, or IAPP), which functions as part of the endocrine pancreas and contributes to glycemic control.
- IAP islet amyloid polypeptide
- Glucagon- producing a-cells are the next most-common cell type.
- the remaining islet cells each comprising a small minority of the total, include ⁇ - cells, which produce somatostatin, PP cells, which produce pancreatic polypeptide; and ⁇ - cells, that produce ghrelin.
- GABA can inhibit autoimmune responses in different models of T cell-mediated autoimmune diseases, enhance Treg responses, inhibit beta-cell apoptosis and promote mouse beta-cell replication.
- GABAA-RS GABAA-receptors
- GABA B -Rs GABAA-receptors
- GABA has a relatively low affinity for its receptors, a fast off-rate and a short half-life in vivo, which may necessitate that patients take several grams of GABA a few times a day, for therapeutic efficacy, which is somewhat cumbersome and reduces patient compliance.
- GABA receptor activating ligands in combination with GABAA-R positive allosteric modulators can promote the replication, and/or survival, and/or function ⁇ e.g., insulin production, sensitivity to blood sugar, etc.) of beta cells in mammal.
- PAMS GABAA-R positive allosteric modulators
- Embodiment 1 A method of promoting the replication, growth, and/or survival, and/or function of beta cells in mammal, said method comprising administering to said mammal a GAB AA receptor positive allosteric modulator (PAM) in an amount sufficient to promote the replication, and/or survival, and/or growth, and/or mass, and/or function of beta cells in said mammal.
- PAM GAB AA receptor positive allosteric modulator
- Embodiment 2 A method of embodiment 1, wherein said GABAA receptor positive allosteric modulator (PAM) is administered in conjunction with a GABA receptor activating ligand.
- PAM GABAA receptor positive allosteric modulator
- Embodiment 4 The method of embodiment 3, wherein the GABA receptor activating ligand when used in conjunction with a PAM is at least 10%, or at least 20%, or at least 30%, or at least 40%, or at least 50%, or at least 60%, or at least 70%, or at least 80%, or at least 90%, or at least 100%, or at least 1.2 fold, or at least 1.5 fold, or at least 2 fold, ro at least 3 fold, or at least 4 fold, or at least 5 fold, or at least 10 fold is more effective to promote the replication, and/or survival, and/or function of beta cells in said mammal than when either agent is administered alone.
- Embodiment 5 The method of embodiment 2, wherein the GABA receptor activating ligand is used at a lower dosage than would be used to achieve the same effect on beta cell replication, and/or survival, and/or function when used alone and/or said positive allosteric modulator is used at a lower dosage than would be used to achieve the activity for which the PAM is designed and/or approved if the PAM were used alone.
- Embodiment 6 The method of embodiment 5, wherein the GABA receptor activating ligand used at less than about 95%, or less than about 90%, or less than about 80%), or less than about 70%, or less than about 60%, or less than about 50%, or less than about 40%), or less than about 30%, or less than about 20%, or less than about 10% of the dosage that would be used to achieve the same effect on beta cell replication, and/or survival, and/or function when the GABA receptor activating ligand is used alone.
- Embodiment 7 The method according to any one of embodiments 5-6, wherein said positive allosteric modulator is used at less than about 95%, or less than about 90%), or less than about 80%, or less than about 70%, or less than about 60%, or less than about 50%), or less than about 40%, or less than about 30%, or less than about 20%, or less than about 10% of the dosage that that would be used to achieve the activity for which the PAM is designed and/or approved if the PAM were used alone.
- Embodiment 8 The method according to any one of embodiments 5-7, where the GABA receptor activating ligand is used at a lower dosage than would be used to achieve the same effect on beta cell replication, and/or survival, and/or function when used alone and/or said positive allosteric modulator is used at a subtherapeutic dosage.
- Embodiment 9 The method according to any one of embodiments 1-8, wherein said administration promotes replication of beta cells.
- Embodiment 10 The method according to any one of embodiments 1-9, wherein said administration increases mass of beta cells.
- Embodiment 11 The method according to any one of embodiments 1-10, wherein said administration promotes survival of beta cells.
- Embodiment 12 The method according to any one of embodiments 1-11, wherein said administration promotes function of beta cells.
- Embodiment 13 The method of embodiment 12, wherein said
- administration increases the insulin content and/or the amount of insulin secreted by beta cells.
- Embodiment 14 The method of embodiment 12, wherein said
- administration promotes function by increasing the number of insulin positive beta cells.
- Embodiment 15 The method according to any one of embodiments 1-14, wherein said mammal is a human.
- Embodiment 16 The method of embodiment 15, wherein said mammal is a human diagnosed with type I diabetes.
- Embodiment 17 The method of embodiment 15, wherein said mammal is diagnosed as pre-diabetic.
- Embodiment 18 The method according to any one of embodiments 1-14, wherein said mammal is a non-human mammal.
- Embodiment 19 The method according to any one of embodiments 1-18, wherein said GABA receptor activating ligand and said PAM act synergistically to improve the replication, and/or survival, and/or growth, and/or function of said beta cells.
- Embodiment 20 The method according to any one of embodiments 1-19, wherein said PAM comprises an agent selected from the group consisting of AP325, and AP3.
- Embodiment 21 The method of embodiment 20, wherein said PAM comprises AP325.
- Embodiment 22 The method of embodiment 21, wherein said AP325 is administered at a dosage lower than that used for neuropathic pain or spinal cord injury.
- Embodiment 23 The method according to any one of embodiments 1-19, wherein said PAM comprises an agent selected from the group consisting of a barbituate, a benzodiazepine, a quinazolinone, and a neurosteroid.
- said PAM comprises an agent selected from the group consisting of a barbituate, a benzodiazepine, a quinazolinone, and a neurosteroid.
- Embodiment 24 The method of embodiment 23, wherein said PAM comprises a barbituate.
- Embodiment 25 The method of embodiment 24, wherein said PAM comprises a barbiturate selected from the group consisting of allobarbital (5,5- diallylbarbiturate), amobarbital (5-ethyl-5-isopentyl-barbiturate), aprobarbital (5-allyl-5- isopropyl-barbiturate), alphenal (5-allyl-5-phenyl-barbiturate), barbital (5,5- diethylbarbiturate), brallobarbital (5-allyl-5-(2-bromo-allyl)-barbiturate), pentobarbital (5- ethyl-5-(l-methylbutyl)-barbiturate), phenobarbital (5-ethyl-5-phenylbarbiturate), secobarbital (5-[(2R)-pentan-2-y
- Embodiment 26 The method of embodiment 23, wherein said PAM comprises a benzodiazepine.
- Embodiment 27 The method of embodiment 26, wherein said PAM comprises a benzodiazepine selected from the group consisting of alprazolam, bromazepam, chlordiazepoxide, midazolam, clonazepam, clorazepate, diazepam, estazolam, flurazepam, halazepam, ketazolam, lorazepam, nitrazepam, oxazepam, prazepam, quazepam, temazepam, and triazolam.
- Embodiment 28 The method of embodiment 26, wherein said PAM comprises alprazolam.
- Embodiment 29 The method of embodiment 28, wherein said alprazolam is administered at a dosage less than that used to treat used to treat an anxiety disorder, a panic disorder, and/or anxiety caused by depression.
- Embodiment 30 The method of embodiment 28, wherein said alprazolam is administered as an immediate release tablet less than 1.5 mg orally per day or less than 1.0 mg orally per day, or less than 0.5 mg orally per day, or as an extended release tablet less than 0.5 mg orally per day, or less than about 0.4 mg orally per day or less than about 3 mg orally per day.
- Embodiment 31 The method of embodiment 26, wherein said PAM comprises midazolam.
- Embodiment 32 The method of embodiment 31, wherein said midazolam is administered at a dosage less than that used to reduce anxiety, or producing drowsiness or anesthesia before medical procedures or surgery, or to maintain sedation or anesthesia.
- Embodiment 33 The method of embodiment 31, wherein said midazolam is administered at a dosage less than 1 mg IV, or less than about 0.8 mg IV, or less than about 0.5 mg IV, or less than about 0.01 mg/kg IV, or less than about 0.07 mg/kg IM, or less than about 0.05 mg/kg IM, or less than about 0.03 mg/kg IM, or less than about 0.01 mg/kg.
- Embodiment 34 The method of embodiment 26, wherein said PAM comprises clonazepam.
- Embodiment 35 The method of embodiment 34, wherein said clonazepam is administered at a dosage less than that used to treat seizure disorders (including absence seizures or Lennox-Gastaut syndrome), or less than that used to treat panic disorder (including agoraphobia) in adults.
- Embodiment 36 The method of embodiment 34, wherein said clonazepam is administered at a dosage less than about 0.5 mg orally per day, or less than about 0.25 mg orally per day, or less than bout 0.01 mg/kg/day, or less than about 0.005 mg/kg/day.
- Embodiment 37 The method of embodiment 23, wherein said PAM comprises a neurosteroid.
- Embodiment 38 The method of embodiment 37, wherein said PAM comprises a neurosteroid selected from the group consisting of allopregnanolone (3a- hydroxy-5a-pregnan-20-one), and pregnanolone.
- Embodiment 39 The method according to any one of embodiments 2-38, wherein said GABA receptor activating ligand comprises GABA.
- Embodiment 40 The method according to any one of embodiments 2-38, wherein said GABA receptor activating ligand comprises an agent selected from the group consisting of bamaluzole, gabamide, GABOB, gaboxadol, ibotenic acid, isoguvacine, isonipecotic acid, muscimol, phenibut, picamilon, progabide, quisqualamine, progabide acid (SL 75102), thiomuscimol, pregabalin, vigabatrin, 6-aminonicotinic acid, homotaurine, and XP13512 [( ⁇ )-l-([(a-isobutanoyloxyethoxy) carbonyl] aminomethyl)-l-cyclohexane acetic acid].
- said GABA receptor activating ligand comprises an agent selected from the group consisting of bamaluzole, gabamide, GABOB, gaboxadol, ibotenic acid, isoguvacine, isoni
- Embodiment 41 The method according to any one of embodiments 1-40, wherein said method increases beta cell survival after islet transplantation.
- Embodiment 42 The method according to any one of embodiments 1-41, wherein said method increases beta cell replication in islets after islet transplantation.
- Embodiment 43 The method according to any one of embodiments 1-40, wherein said method is performed after islet implantation in order to reduce ⁇ -cell loss due to hypoxia and stress.
- Embodiment 44 The method according to any one of embodiments 1-43, where said method is performed for up to 3 days post implantation, or for up to 1 week post implantation, or for up to 2 weeks post implantation, or for up to 3 weeks post implantation, or for up to 4 weeks post implantation, or for up to 5 weeks post implantation, or for up to 6 weeks post implantation, or for up to 7 weeks post implantation, or for up to 8 weeks post implantation, or for up to 3 months post implantation, or for up to 4 months post
- Embodiment 45 The method according to any one of embodiments 2-44, wherein said GABA receptor activating ligand is not an alcohol.
- Embodiment 46 The method according to any one of embodiments 2-45, wherein said GABA receptor activating ligand is not a kavalactone.
- Embodiment 47 The method according to any one of embodiments 2-46, wherein said GABA receptor activating ligand is not skullcap or a skullcap constituent.
- Embodiment 48 The method according to any one of embodiments 2-47, wherein said GABA receptor activating ligand is not valerian or a valerian constituent.
- Embodiment 49 The method according to any one of embodiments 2-48, wherein said GABA receptor activating ligand is not a volatile gas.
- Embodiment 50 The method according to any one of embodiments 1-49, wherein said mammal is not under treatment for one or more conditions selected from the group consisting of neuropathic pain, spinal cord injury, an anxiety disorder, a panic disorder, anxiety caused by depression, a seizure disorder (including absence seizures or Lennox-Gastaut syndrome), and catamenial epilepsy.
- Embodiment 51 The method according to any one of embodiments 1-50, wherein said PAM is not administered to produce drowsiness or anesthesia before a medical procedure or surgery, or to maintain sedation or anesthesia.
- Embodiment 52 The method according to any one of embodiments 1-51, wherein said PAMS that are BBB-permeable are administered at doses below those used for CNS indications.
- Embodiment 53 A pharmaceutical formulation comprising a GABA receptor activating ligand and a GABAA receptor positive allosteric modulator (PAM).
- PAM GABAA receptor positive allosteric modulator
- Embodiment 54 The formulation of embodiment 53, wherein the GABA receptor activating ligand is present at a lower unit dosage than in a therapeutic formulation comprising a GABA receptor activating ligand alone and/or the PAM is at a lower unit dosage than in a therapeutic formulation comprising the PAM alone.
- Embodiment 55 The formulation of embodiment 54, wherein the GABA receptor activating ligand is present at a lower unit dosage than in a therapeutic formulation comprising GABA or a GABA analog alone.
- Embodiment 56 The formulation of embodiment 55, wherein the GABA receptor activating ligand present at less than about 95%, or less than about 90%, or less than about 80%>, or less than about 70%, or less than about 60%, or less than about 50%, or less than about 40%, or less than about 30%, or less than about 20%, or less than about 10% of the dosage that would be provided to achieve the same effect on beta cell replication, and/or survival, and/or function when the GABA receptor activating ligand is present alone.
- Embodiment 57 The formulation according to any one of embodiments of embodiment 53-56, wherein the PAM is at a lower unit dosage than in a therapeutic formulation comprising the PAM alone.
- Embodiment 58 The formulation of embodiment 57, wherein said positive allosteric modulator is present at less than about 95%, or less than about 90%, or less than about 80%), or less than about 70%, or less than about 60%, or less than about 50%, or less than about 40%, or less than about 30%, or less than about 20%, or less than about 10% of the amount that that would be present to achieve the activity for which the PAM is designed and/or approved if the PAM were used alone.
- Embodiment 59 The formulation according to any one of embodiments 53-
- Embodiment 60 The formulation according to any one of embodiments 53-
- Embodiment 61 The formulation according to any one of embodiments 53-
- said GABA receptor activating ligand and said PAM are present in a concentration sufficient provide at least 10%, or at least 20%, or at least 30%, or at least 40%, or at least 50%, or at least 60%, or at least 70%, or at least 80%, or at least 90%, or at least 100%), or at least 1.2 fold, or at least 1.5 fold, or at least 2 fold, or at least 3 fold, or at least 4 fold, or at least 5 fold, or at least 10 fold greater efficacy in promoting the replication, and/or survival, and/or function of beta cells in a mammal than when either agent is administered alone.
- Embodiment 62 The formulation according to any one of embodiments 53-
- said PAM comprises an agent selected from the group consisting of a barbituate, a benzodiazepine, a quinazolinone, and a neurosteroid.
- Embodiment 63 The formulation of embodiment 62, wherein said PAM comprises a barbituate.
- Embodiment 64 The formulation of embodiment 63, wherein said PAM comprises a barbiturate selected from the group consisting of allobarbital (5,5- diallylbarbiturate), amobarbital (5-ethyl-5-isopentyl-barbiturate), aprobarbital (5-allyl-5- isopropyl-barbiturate), alphenal (5-allyl-5-phenyl-barbiturate), barbital (5,5- diethylbarbiturate), brallobarbital (5-allyl-5-(2-bromo-allyl)-barbiturate), pentobarbital (5- ethyl-5-(l-methylbutyl)-barbiturate), phenobarbital (5-ethyl-5-phenylbarbiturate), secobarbital (5-[(2R)-pentan-2-yl]-5-prop-2-enyl-barbiturate).
- Embodiment 65 Embodiment 65:
- Embodiment 66 The formulation of embodiment 65, wherein said PAM comprises a benzodiazepine selected from the group consisting of alprazolam, bromazepam, chlordiazepoxide, midazolam, clonazepam, clorazepate, diazepam, estazolam, flurazepam, halazepam, ketazolam, lorazepam, nitrazepam, oxazepam, prazepam, quazepam, temazepam, and triazolam.
- Embodiment 67 The formulation of embodiment 65, wherein said PAM comprises alprazolam.
- Embodiment 68 The formulation of embodiment 65, wherein said PAM comprises midazolam.
- Embodiment 69 The formulation of embodiment 65, wherein said PAM comprises clonazepam.
- Embodiment 70 The formulation of embodiment 62, wherein said PAM comprises a neurosteroid.
- Embodiment 71 The formulation of embodiment 70, wherein said PAM comprises a neurosteroid selected from the group consisting of allopregnanolone, and pregnanolone.
- Embodiment 72 The formulation according to any one of embodiments 53-
- GABA receptor activating ligand comprises GABA
- Embodiment 73 The formulation according to any one of embodiments 53- 71 , wherein said GABA receptor activating ligand an agent selected from the group consisting of bamaluzole, gabamide, GABOB, gaboxadol, ibotenic acid, isoguvacine, isonipecotic acid, muscimol, phenibut, picamilon, progabide, quisqualamine, progabide acid (SL 75102), thiomuscimol, pregabalin, vigabatrin, 6-aminonicotinic acid, homotaurine, and XP 13512 [( ⁇ )-l-([(a-isobutanoyloxyethoxy) carbonyl] aminomethyl)-l-cyclohexane acetic acid].
- said GABA receptor activating ligand an agent selected from the group consisting of bamaluzole, gabamide, GABOB, gaboxadol, ibotenic acid, isoguvacine,
- Embodiment 74 The formulation according to any one of embodiments 53-
- Embodiment 75 The formulation according to any one of embodiments 53-
- Embodiment 76 The formulation according to any one of embodiments 53-
- GABA receptor activating ligand is not skullcap or a skullcap constituent.
- Embodiment 77 The formulation according to any one of embodiments 53-
- Embodiment 78 A kit for promoting the replication in a mammal of cells that express GABAA receptors, said kit comprising: a container containing a GABA receptor activating ligand; and a container containing a GABAA receptor positive allosteric modulator (PAM).
- PAM GABAA receptor positive allosteric modulator
- Embodiment 79 The kit of embodiment 78 where the GABA receptor activating ligand and the PAM are in the same container.
- Embodiment 80 The kit of embodiment 78 where the GABA receptor activating ligand and the PAM are in separate containers.
- Embodiment 81 The kit according to any one of embodiments 78-80, wherein the GABA receptor activating ligand is present at a lower unit dosage than in a therapeutic formulation comprising GABA or a GABA analog alone and/or the PAM is at a lower unit dosage than in a therapeutic formulation comprising the PAM alone.
- Embodiment 82 The kit according to any one of embodiments 78-80, wherein the GABA receptor activating ligand is present at a lower unit dosage than in a therapeutic formulation comprising GABA or a GABA analog alone.
- Embodiment 83 The kit of embodiment 82, wherein the GABA receptor activating ligand present at less than about 95%, or less than about 90%, or less than about 80%), or less than about 70%, or less than about 60%>, or less than about 50%, or less than about 40%), or less than about 30%>, or less than about 20%, or less than about 10%> of the dosage that would be provided to achieve the same effect on beta cell replication, and/or survival, and/or function when the GABA receptor activating ligand is present alone.
- Embodiment 84 The kit according to any one of embodiments 78-83, wherein the PAM is at a lower unit dosage than in a therapeutic formulation comprising the PAM alone.
- Embodiment 85 The kit according to any one of embodiments 78-84 wherein said positive allosteric modulator is present at less than about 95%, or less than about 90%), or less than about 80%, or less than about 70%, or less than about 60%, or less than about 50%, or less than about 40%, or less than about 30%, or less than about 20%, or less than about 10% of the amount that that would be present to achieve the activity for which the PAM is designed and/or approved if the PAM were used alone.
- Embodiment 86 The kit according to any one of embodiments 78-85, wherein said GABA receptor activating ligand and said PAM are present in a concentration sufficient to provide synergistic activity in stimulating replication of cells expressing a GABA A receptor.
- Embodiment 87 The kit of according to any one of embodiments 78-85, wherein said GABA receptor activating ligand and said PAM are present in a concentration sufficient to provide synergistic activity in stimulating replication of beta cells and/or promoting survival of beta cells and/or improving function of beta cells.
- Embodiment 88 The kit according to any one of embodiments 78-87, wherein said GABA receptor activating ligand and said PAM are present in a concentration sufficient provide at least 10%, or at least 20%, or at least 30%, or at least 40%, or at least 50%, or at least 60%, or at least 70%, or at least 80%, or at least 90%, or at least 100%, or at least 1.2 fold, or at least 1.5 fold, or at least 2 fold, or at least 3 fold, or at least 4 fold, or at least 5 fold, or at least 10 fold greater efficacy in promoting the replication, and/or survival, and/or function of beta cells in a mammal than when either agent is administered alone.
- Embodiment 89 The kit according to any one of embodiments 78-88, wherein said PAM comprises an agent selected from the group consisting of a barbituate, a benzodiazepine, a quinazolinone, and a neurosteroid.
- said PAM comprises an agent selected from the group consisting of a barbituate, a benzodiazepine, a quinazolinone, and a neurosteroid.
- Embodiment 90 The kit of embodiment 89, wherein said PAM comprises a barbituate.
- Embodiment 91 The kit of embodiment 90, wherein said PAM comprises a barbiturate selected from the group consisting of allobarbital (5,5-diallylbarbiturate), amobarbital (5-ethyl-5-isopentyl-barbiturate), aprobarbital (5-allyl-5-isopropyl-barbiturate), alphenal (5-allyl-5-phenyl-barbiturate), barbital (5,5-diethylbarbiturate), brallobarbital (5- allyl-5-(2-bromo-allyl)-barbiturate), pentobarbital (5-ethyl-5-(l-methylbutyl)-barbiturate), phenobarbital (5-ethyl-5-phenylbarbiturate), secobarbital (5-[(2R)-pentan-2-yl]-5-prop-2- enyl-barbiturate).
- allobarbital (5,5-dially
- Embodiment 92 The kit of embodiment 89, wherein said PAM comprises a benzodiazepine.
- Embodiment 93 The kit of embodiment 92, wherein said PAM comprises a benzodiazepine selected from the group consisting of alprazolam, bromazepam,
- Embodiment 94 The kit of embodiment 92, wherein said PAM comprises alprazolam.
- Embodiment 95 The kit of embodiment 92, wherein said PAM comprises clonazepam.
- Embodiment 96 The kit of embodiment 92, wherein said PAM comprises midazolam.
- Embodiment 97 The kit of embodiment 89, wherein said PAM comprises a neurosteroid.
- Embodiment 98 The kit of embodiment 97, wherein said PAM comprises a neurosteroid selected from the group consisting of allopregnanolone, and pregnanolone.
- Embodiment 99 The kit according to any one of embodiments 78-98, wherein said GABA receptor activating ligand comprises GABA.
- Embodiment 100 The kit according to any one of embodiments 78-98, wherein said GABA receptor activating ligand comprises an agent selected from the group consisting of bamaluzole, gabamide, GABOB, gaboxadol, ibotenic acid, isoguvacine, isonipecotic acid, muscimol, phenibut, picamilon, progabide, quisqualamine, progabide acid (SL 75102), thiomuscimol, pregabalin, vigabatrin, 6-aminonicotinic acid, homotaurine, and XP13512 [( ⁇ )-l-([(a-isobutanoyloxyethoxy) carbonyl] aminomethyl)-l-cyclohexane acetic acid].
- Embodiment 101 The kit according to any one of embodiments 78-100, wherein said GABA receptor activating ligand is not an alcohol.
- Embodiment 102 The kit according to any one of embodiments 78-101, wherein said GABA receptor activating ligand is not a kavalactone.
- Embodiment 103 The kit according to any one of embodiments 78-102, wherein said GABA receptor activating ligand is not skullcap or a skullcap constituent.
- Embodiment 104 The kit according to any one of embodiments 78-103, wherein said GABA receptor activating ligand is not valerian or a valerian constituent.
- GABA A receptor activating ligand refers to an agent that is an agonist for one or more of the GABA receptors. In certain embodiments, the GABA receptor activating ligand is an agonist for at least the GABA A receptor.
- PAM positive allosteric modulator of the GABAA receptor
- GABAA PAMS do not bind at the same active site as the gamma-aminobutyric acid (GABA) neurotransmitter molecule.
- the PAMs trigger or potentiate the GABAA receptor to open its chloride channel.
- beta cell function refers to the function of beta cells, particularly with respect to insulin production, secretion, and ⁇ -cell area.
- Increase in beta cell function refers to an increase in insulin content of beta cells and/or an increase in insulin secretion by beta cells and/or an increase in the number of insulin positive beta cells.
- subtherapeutic dosage when used with respect to a PAM refers to a dosage below the approved and/or recommended and/or recognized dosage of the PAM when used for the activity for which the PAM was originally designed and/or approved.
- the subtherapeutic dosage of a benzodiazepine such as alprazolam refers to a dosage below the approved and/or recommended and/or recognized dosage of that benzodiazepine for depression, panic disorder, and/or anxiety.
- the subtherapeutic dosage is less than 90% or less than about 80%, or less than about 70%, or less than about 60%, or less than about 50%, or less than about 40%, or less than about 30%), or less than about 20%, or less than about 10% of the recommended dosage for the activity for which the PAM was designed and/or approved (e.g., depression, panic disorder, and/or anxiety).
- the phrases "in conjunction with” or “in combination with” when used in reference to the use of the active agent(s) described herein (e.g., one or more GABA receptor activating ligand(s)) in conjunction with one or more other drugs described herein (e.g., one or more PAMs) indicates that the GABA receptor activating ligand(s) and the PAM(s) are administered so that there is at least some chronological overlap in their physiological activity on the organism, and in particular on beta cells.
- the GABA receptor activating ligand (s) and PAM(s) can be administered simultaneously and/or sequentially.
- Figure 1 shows a schematic diagram illustrating GAB A receptor subunits.
- FIG. 4 Panel A and B, shows that with midazolam enhanced the proliferation of INS-1 cells.
- Panel A) Shows the results over a broad dosage range in steps of 10-fold.
- Panel B) Shows results over a smaller dose range in smaller dose increments.
- FIG. 5 Panel An and B, shows that treatment with midazolam or clonazepam enhances GABA-induced INS-1 cell proliferation in vitro.
- Figure 6 shows that treatment with AP325 or AP3 does not stimulate INS-1 cell proliferation in vitro. Data are expressed as the mean ⁇ SD of % cell proliferation, relative to the control without any treatment from at least three separate experiments. The control cell proliferation was designated as 100.
- Figure 7 shows that AP325 enhances GABA-stimulated INS-1 cell proliferation in vitro. Data are expressed as the mean ⁇ SD of cell proliferation relative to the control without any treatment from at least three separate experiments. The control cell proliferation was designated as 1.
- Figure 8 shows that AP3 enhances GABA-induced INS-1 cell proliferation in vitro. Data are expressed as the mean ⁇ SD of relative cell proliferation to the control without any treatment from at three separate experiments. The control cell proliferation was designated as 1. Treatments that induced significant differences from the control are stated in the Example 3).
- FIG. 9 panels A-H: Panel A) GAD enzymatic activity in INS-1 cells.
- INS-1 cells and 293T cells were stored at -80 C until use.
- the samples were homogenized into GAD activity assay buffer with protease inhibitors.
- the GAD enzymatic activity within homogenates was assessed using a standard C0 2 trapping assay (in quadruplicate) as previously described (Kaufman et al. (1991) J. Neurochem. 56: 720-723). Data shown is average CPM +/- SEM from a representative assay from three experiments.
- Panel B Effect of PAMs on INS-1 cell proliferation. INS-1 cells were cultured with the indicated PAM at a dose range of 10 "9 to 10 "6 M and assessed for their proliferation.
- INS-1 cells were cultured with GABA (0.3 mM) and midazolam or clonazepam (100 nM) with, or without, the TSPO inhibitor PK11195 (1 uM) for 48 hrs.
- FIG 10 shows that alprazolam enhances human islet cell replication.
- Fresh human islets were treated with the indicated dosage of GABA, together with, or without, the indicated PAM as described in Methods. Data shown are the average rate of proliferation relative to that of cultures with media alone (designated as 1).
- N two independent studies with triplicate cultures. The results were very similar in both studies. *p ⁇ 0.05
- FIG 11 shows that the GABA-binding site blocker/inhibit bicuculline ablates the ability of alprazolam to enhance islet cell replication.
- Human islets were incubated with alprazolam (100 nM) together with a standard dose range of bicuculline (0- 50 uM). Data shown are the average rate of proliferation relative to that of cultures with media alone (designated as 1).
- Figure 12 shows that alprazolam enhances GABA' s ability to promote human islet cell replication. Human islets were incubated with a dose range of GABA together with alprazolam (100 ng/ml) for 4 days with 3 H thymidine.
- compositions and methods described herein pertain to the discovery that GABA receptor activating ligands in combination with a positive allosteric modulator of GABAA receptors can promote the replication, and/or survival, and/or function of beta cells in mammal. Moreover use of the GABA receptor activating ligand in combination with the positive allosteric modulator provides a significantly greater effect on beta cell replication and/or survival, and/or function than the GABA receptor activating ligand used alone. Without being bound to a particular theory it appears that the combination of a GABA receptor activating ligand and a PAM has a synergistic effect on beta cell replication and/or survival, and/or function.
- the GABA receptor activating ligand and/or the PAM can be used at a dosage lower than would be used if the GABA receptor activating ligand or PAM was used alone to promote the replication, and/or survival, and/or function of beta cells in mammal (e.g., in a mammal receiving an islet cell transplant).
- methods of promoting the replication, and/or survival, and/or function of beta cells in mammal involve administering to a mammal in need thereof (e.g., a subject receiving an islet cell transplant) a GABA receptor activating ligand in conjunction with a GABAA receptor positive allosteric modulator (PAM) where the GABA receptor activating ligand is used at a lower dosage than would be used to achieve the same effect on beta cell replication, and/or survival, and/or function than when used alone and/or said positive allosteric modulator is used at a subtherapeutic dosage.
- a mammal in need thereof e.g., a subject receiving an islet cell transplant
- PAM GABAA receptor positive allosteric modulator
- the administration of both agents promotes replication of beta cells.
- the administration of both agents promotes survival of beta cells. In certain embodiments the administration of both agents promotes function of beta cells (e.g. increases insulin content and/or secretion). In certain embodiments the administration of both agents increases the number of insulin positive beta cells.
- pharmaceutical formulations are provided that comprise a GABA receptor activating ligand and a GABA A receptor positive allosteric modulator (PAM). In certain embodiments kits for the practice of the methods described herein are also contemplated.
- kits comprises a container containing a GABA receptor activating ligand and a container containing a GAB AA receptor positive allosteric modulator (PAM), and optionally instructional materials teaching, inter alia, the use of these agents in the methods described herein.
- PAM GAB AA receptor positive allosteric modulator
- GABA receptor activating ligands are well known to those of skill in the art.
- Such ligands include for example gamma-aminobutyric acid (GABA) the native ligand for the GABA receptor.
- GABA receptor activating ligands include, but are not limited to homotaurine, bamaluzole, gabamide, GABOB, gaboxadol, ibotenic acid, isoguvacine, isonipecotic acid, muscimol, phenibut, picamilon, progabide, quisqualamine, progabide acid (SL 75102), thiomuscimol, pregabalin, vigabatrin, 6-aminonicotinic acid, XP13512 (( ⁇ )-l- ([(a-isobutanoyloxyethoxy) carbonyl] aminomethyl)-l-cyclohexane acetic acid), and the like.
- GABA receptor activating ligands are intended to be illustrative and non-limiting.
- Other GABA receptor activating ligands are known to those of skill in the art and their use in the methods, formulations, and kits described herein is contemplated.
- PAM GABAA receptor positive allosteric modulator
- PAMS Positive allosteric modulators
- Illustrative PAMS include, but are not limited to alcohols ⁇ e.g., ethanol, isopropanol), avermectins ⁇ e.g., ivermectin), barbiturates ⁇ e.g., phenobarbital),
- benzodiazepines bromides ⁇ e.g., potassium bromide, carbamates ⁇ e.g., meprobamate, carisoprodol), chloralose, chlormezanone, clomethiazole, dihydroergolines ⁇ e.g., ergoloid (dihydroergotoxine)), etazepine, etifoxine, imidazoles ⁇ e.g., etomidate), kavalactones (found in kava), loreclezole, neuroactive steroids ⁇ e.g., allopregnanolone, ganaxolone),
- nonbenzodiazepines ⁇ e.g., zaleplon, Zolpidem, zopiclone, eszopiclone), petri chloral, phenols (e.g., propofol), piped dinedi ones (e.g., glutethimide, methyprylon), propanidid,
- pyrazolopyri dines e.g., etazolate
- quinazolinones e.g., methaqualone
- skullcap constituents e.g. constituents of Scutellaria sp. includinb, but not limited to flavonoids such as baicalein
- stiripentol e.g., stiripentol
- sulfonylalkanes e.g., sulfonmethane, tetronal, trional
- valerian constituents e.g., valeric acid, valerenic acid
- certain volatiles/gases e.g., chloral hydrate, chloroform, diethyl ether, sevoflurane
- the PAMs used in combination with the GABA receptor activating ligands exclude alcohols, and/or kavalactones, and/or skullcap or skullcap constituents, and/or valerian or valerian constituents, and/or volatile gases.
- the PAM comprises an agent selected from the group consisting of a barbituate, a benzodiazepine, a quinazolinone, and a neurosteroid.
- Illustrative barbituates include, but are not limited to allobarbital (5,5-diallylbarbiturate), amobarbital (5-ethyl-5-isopentyl-barbiturate), aprobarbital (5-allyl-5-isopropyl-barbiturate), alphenal (5-allyl-5-phenyl-barbiturate), barbital (5,5-diethylbarbiturate), brallobarbital (5- allyl-5-(2-bromo-allyl)-barbiturate), pentobarbital (5-ethyl-5-(l-methylbutyl)-barbiturate), phenobarbital (5-ethyl-5-phenylbarbiturate), secobarbital (5-[(2R)-pentan-2-yl]-5-prop-2- enyl-barbiturate), and the like.
- Illustrative benzodiazepines include, but are not limited to alprazolam, bromazepam, chlordiazepoxide, clonazepam, clorazepate, diazepam, estazolam, flurazepam, halazepam, ketazolam, lorazepam, nitrazepam, oxazepam, prazepam, quazepam, temazepam, triazolam, and the like.
- Illustrative neurosteroids include, but are not limited to allopregnanolone, and pregnanolone.
- the PAM of particular use comprises alprazolam (XANAX®).
- PAMs are intended to be illustrative and non-limiting. Other PAMs are known to those of skill in the art and their use in the methods, formulations, and kits described herein is contemplated.
- compositions that comprise one or more GABA receptor activating ligands and one or more positive allosteric modulators of the GAB AA receptor.
- the GABA receptor activating ligand is present at a lower unit dosage than in a therapeutic formulation comprising a GABA receptor activating ligand alone and/or the PAM is at a lower unit dosage than in a typical, and/or approved, and/or recommended therapeutic formulation comprising the PAM alone.
- GABA receptor ligand in the combined formulation comprises one or more of gamma-aminobutyric acid (GABA), homotaurine, bamaluzole, gabamide, GABOB, gaboxadol, ibotenic acid, isoguvacine, isonipecotic acid, muscimol, phenibut, picamilon, progabide, quisqualamine, progabide acid (SL 75102), thiomuscimol, pregabalin, vigabatrin, 6-aminonicotinic acid, XP13512 (( ⁇ )-l-([(a-isobutanoyloxyethoxy) carbonyl] aminomethyl)-l-cyclohexane acetic acid), and the like, e.g., as described herein.
- GABA gamma-aminobutyric acid
- homotaurine gamma-aminobutyric acid
- bamaluzole gabamide
- GABOB ga
- the PAM in the combined formulation comprises one or more of an alcohol (e.g., ethanol, isopropanol), avermectins (e.g., ivermectin), barbiturates (e.g., phenobarbital), benzodiazepines, bromides (e.g., potassium bromide, carbamates (e.g., meprobamate, carisoprodol), chloralose, chlormezanone, clomethiazole, dihydroergolines (e.g., ergoloid (dihydroergotoxine)), etazepine, etifoxine, imidazoles (e.g., etomidate), kavalactones (found in kava), loreclezole, neuroactive steroids (e.g., allopregnanolone, ganaxolone), nonbenzodiazepines (e.g.,
- constituents of Scutellaria sp. includinb include flavonoids such as baicalein), stiripentol, sulfonylalkanes (e.g., sulfonmethane, tetronal, trional), valerian constituents (e.g., valeric acid, valerenic acid).
- the PAMs used in combination with the GABA receptor activating ligands exclude alcohols, and/or kavalactones, skullcap or skullcap constituents, and the like, e.g., as described herein.
- the combined formulation comprises GABA and alprazolam.
- the active agent(s) can be formulated and administered in the "native" form or, if desired, in the form of salts, esters, amides, prodrugs, derivatives, and the like, provided the salt, ester, amide, prodrug or derivative is suitable pharmacologically, i.e., effective in the present method(s).
- Salts, esters, amides, prodrugs and other derivatives of the active agents can be prepared using standard procedures known to those skilled in the art of synthetic organic chemistry and described, for example, by March (1992) Advanced Organic Chemistry; Reactions, Mechanisms and Structure, 4th Ed. N. Y. Wiley-Interscience, and as described above..
- a pharmaceutically acceptable salt can be prepared for any of the agent(s) described herein ⁇ e.g., GAB A receptor activating ligand(s) and PAM(s) described herein) having a functionality capable of forming a salt.
- a pharmaceutically acceptable salt is any salt that retains the activity of the parent compound and does not impart any deleterious or untoward effect on the subject to which it is administered and in the context in which it is administered.
- pharmaceutically acceptable salts may be derived from organic or inorganic bases.
- the salt may be a mono or polyvalent ion. Of particular interest are the inorganic ions, lithium, sodium, potassium, calcium, and magnesium.
- Organic salts may be made with amines, particularly ammonium salts such as mono-, di- and trialkyl amines or ethanol amines. Salts may also be formed with caffeine, tromethamine and similar molecules.
- salts can be prepared from the free base using conventional methodology that typically involves reaction with a suitable acid.
- a suitable acid such as methanol or ethanol
- the base form of the drug is dissolved in a polar organic solvent such as methanol or ethanol and the acid is added thereto.
- the resulting salt either precipitates or can be brought out of solution by addition of a less polar solvent.
- Suitable acids for preparing acid addition salts include, but are not limited to both organic acids, e.g., acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, malic acid, malonic acid, succinic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid, and the like, as well as inorganic acids, e.g., hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like.
- organic acids e.g., acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, malic acid, malonic acid, succinic acid, maleic acid, fumaric acid, tartaric acid, cit
- An acid addition salt can be reconverted to the free base by treatment with a suitable base.
- Certain particularly preferred acid addition salts of the active agents herein include halide salts, such as may be prepared using hydrochloric or hydrobromic acids.
- preparation of basic salts of the active agents of this invention are prepared in a similar manner using a pharmaceutically acceptable base such as sodium hydroxide, potassium hydroxide, ammonium hydroxide, calcium hydroxide, trimethylamine, or the like.
- Particularly preferred basic salts include alkali metal salts, e.g., the sodium salt, and copper salts.
- the pKa of the counterion is preferably at least about 2 pH units lower than the pKa of the drug.
- the pKa of the counterion is preferably at least about 2 pH units higher than the pKa of the drug. This permits the counterion to bring the solution's pH to a level lower than the pH max to reach the salt plateau, at which the solubility of salt prevails over the solubility of free acid or base.
- the generalized rule of difference in pKa units of the ionizable group in the active pharmaceutical ingredient (API) and in the acid or base is meant to make the proton transfer energetically favorable.
- the counterion is a pharmaceutically acceptable counterion.
- Suitable anionic salt forms include, but are not limited to acetate, benzoate, benzylate, bitartrate, bromide, carbonate, chloride, citrate, edetate, edisylate, estolate, fumarate, gluceptate, gluconate, hydrobromide, hydrochloride, iodide, lactate, lactobionate, malate, maleate, mandelate, mesylate, methyl bromide, methyl sulfate, mucate, napsylate, nitrate, pamoate (embonate), phosphate and diphosphate, salicylate and disalicylate, stearate, succinate, sulfate, tartrate, tosylate, triethiodide, valerate, and the like, while suitable cationic salt forms include, but are not limited to aluminum, benzathine, calcium, ethylene diamine,
- esters typically involves functionalization of hydroxyl and/or carboxyl groups that are present within the molecular structure of the active agent.
- the esters are typically acyl- substituted derivatives of free alcohol groups, i.e., moieties that are derived from carboxylic acids of the formula RCOOH where R is alky, and preferably is lower alkyl.
- Esters can be reconverted to the free acids, if desired, by using conventional hydrogenolysis or hydrolysis procedures.
- Amides can also be prepared using techniques known to those skilled in the art or described in the pertinent literature.
- amides may be prepared from esters, using suitable amine reactants, or they may be prepared from an anhydride or an acid chloride by reaction with ammonia or a lower alkyl amine.
- the active agents identified herein e.g., combined
- GABA receptor activating ligand(s) and PAM(s)) are useful for parenteral administration, topical administration, oral administration, nasal administration (or otherwise inhaled), rectal administration, or local administration, such as by aerosol or transdermally, for promoting the replication, and/or survival, and/or function of beta cells in mammal.
- the active agents described herein can also be combined with a pharmaceutically acceptable carrier(s) (excipient(s)) to form a
- Pharmaceutically acceptable carriers can contain one or more physiologically acceptable compound(s) that act, for example, to stabilize the composition or to increase or decrease the absorption of the active agent(s).
- physiologically acceptable compounds can include, for example, carbohydrates, such as glucose, sucrose, or dextrans, antioxidants, such as ascorbic acid or glutathione, chelating agents, low molecular weight proteins, protection and uptake enhancers such as lipids, compositions that reduce the clearance or hydrolysis of the active agents, or excipients or other stabilizers and/or buffers.
- physiologically acceptable compounds particularly of use in the preparation of tablets, capsules, gel caps, and the like include, but are not limited to binders, diluent/fillers, disintegrants, lubricants, suspending agents, and the like.
- an oral dosage form e.g., a tablet
- an excipient e.g., lactose, sucrose, starch, mannitol, etc.
- an optional disintegrator e.g. calcium carbonate, carboxymethylcellulose calcium, sodium starch glycollate, crospovidone etc.
- a binder e.g. alpha-starch, gum arabic, microcrystalline cellulose
- Suitable coating materials include, but are not limited to ethyl-cellulose, hydroxymethylcellulose, POLYOX®yethylene glycol, cellulose acetate phthalate, hydroxypropylmethylcellulose phthalate, and Eudragit (Rohm & Haas, Germany;
- physiologically acceptable compounds include wetting agents, emulsifying agents, dispersing agents or preservatives that are particularly useful for preventing the growth or action of microorganisms.
- Various preservatives are well known and include, for example, phenol and ascorbic acid.
- pharmaceutically acceptable carrier(s) including a physiologically acceptable compound depends, for example, on the route of administration of the active agent(s) and on the particular physiochemical characteristics of the active agent(s).
- the excipients are sterile and generally free of undesirable matter. These compositions can be sterilized by conventional, well-known sterilization techniques. For various oral dosage form excipients such as tablets and capsules sterility is not required. The USP/NF standard is usually sufficient.
- the pharmaceutical compositions can be administered in a variety of unit dosage forms depending upon the method of administration.
- Suitable unit dosage forms include, but are not limited to powders, tablets, pills, capsules, lozenges, suppositories, patches, nasal sprays, injectibles, implantable sustained-release formulations, mucoadherent films, topical varnishes, lipid complexes, etc.
- compositions comprising the active agents described herein (e-g-, GAB A receptor activating ligand(s) and PAM(s)) can be manufactured by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping or lyophilizing processes.
- Pharmaceutical compositions can be formulated in a conventional manner using one or more physiologically acceptable carriers, diluents, excipients or auxiliaries that facilitate processing of the active agent(s) into preparations that can be used pharmaceutically. Proper formulation is dependent upon the route of administration chosen.
- the combined active agents are formulated for oral administration.
- suitable formulations or oral administration can be readily prepared by combining the active agent(s) with pharmaceutically acceptable carriers suitable for oral delivery well known in the art.
- Such carriers enable the active agent(s) described herein to be formulated as tablets, pills, dragees, caplets, lizenges, gelcaps, capsules, liquids, gels, syrups, slurries, suspensions and the like, for oral ingestion by a patient to be treated.
- suitable excipients can include fillers such as sugars (e.g., lactose, sucrose, mannitol and sorbitol), cellulose preparations (e.g., maize starch, wheat starch, rice starch, potato starch, gelatin, gum tragacanth, methyl cellulose, hydroxypropylmethyl-cellulose, sodium carboxymethylcellulose), synthetic polymers (e.g., polyvinylpyrrolidone (PVP)), granulating agents; and binding agents.
- sugars e.g., lactose, sucrose, mannitol and sorbitol
- cellulose preparations e.g., maize starch, wheat starch, rice starch, potato starch, gelatin, gum tragacanth, methyl cellulose, hydroxypropylmethyl-cellulose, sodium carboxymethylcellulose
- synthetic polymers e.g., polyvinylpyrrolidone (PVP)
- disintegrating agents may be added, such as the cross-linked polyvinylpyrrolidone, agar, or alginic acid or a salt thereof such as sodium alginate.
- solid dosage forms may be sugar-coated or enteric-coated using standard techniques. The preparation of enteric-coated particles is disclosed for example in U.S. Pat. Nos. 4,786,505 and 4,853,230.
- the active agent(s) e.g., GAB A receptor activating ligand(s) and PAM(s) described herein
- the active agent(s) are conveniently delivered in the form of an aerosol spray from pressurized packs or a nebulizer, with the use of a suitable propellant, e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas.
- a suitable propellant e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas.
- the dosage unit can be determined by providing a valve to deliver a metered amount.
- Capsules and cartridges of e.g. gelatin for use in an inhaler or insufflator may be formulated containing a powder mix of the compound and a suitable powder base such as lacto
- the active agents described herein are formulated for systemic administration (e.g., as an injectable) in accordance with standard methods well known to those of skill in the art.
- Systemic formulations include, but are not limited to, those designed for administration by injection, e.g. subcutaneous, intravenous,
- the active agents described herein can be formulated in aqueous solutions, preferably in
- physiologically compatible buffers such as Hanks solution, Ringer's solution, or
- physiological saline buffer and/or in certain emulsion formulations can contain formulatory agents such as suspending, stabilizing and/or dispersing agents.
- the active agent(s) can be provided in powder form for constitution with a suitable vehicle, e.g., sterile pyrogen-free water, before use.
- a suitable vehicle e.g., sterile pyrogen-free water
- penetrants appropriate to the barrier to be permeated can be used in the formulation. Such penetrants are generally known in the art. Injectable formulations and inhalable formulations are generally provided as a sterile or substantially sterile formulation.
- the active agents e.g., g., glycyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N
- GABA receptor activating ligand(s) and PAM(s) described herein) may also be formulated as a depot preparations. Such long acting formulations can be administered by implantation (for example subcutaneously or intramuscularly) or by intramuscular injection.
- the active agent(s) may be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.
- the active agent(s) described herein can also be delivered through the skin using conventional transdermal drug delivery systems, i.e., transdermal "patches” wherein the active agent(s) are typically contained within a laminated structure that serves as a drug delivery device to be affixed to the skin.
- the drug composition is typically contained in a layer, or "reservoir,” underlying an upper backing layer.
- the term “reservoir” in this context refers to a quantity of "active ingredient(s)" that is ultimately available for delivery to the surface of the skin.
- the "reservoir” may include the active ingredient(s) in an adhesive on a backing layer of the patch, or in any of a variety of different matrix formulations known to those of skill in the art.
- the patch may contain a single reservoir, or it may contain multiple reservoirs.
- the reservoir comprises a polymeric matrix of a pharmaceutically acceptable contact adhesive material that serves to affix the system to the skin during drug delivery.
- suitable skin contact adhesive materials include, but are not limited to, polyethylenes, polysiloxanes, polyisobutylenes, polyacrylates, polyurethanes, and the like.
- the drug-containing reservoir and skin contact adhesive are present as separate and distinct layers, with the adhesive underlying the reservoir which, in this case, may be either a polymeric matrix as described above, or it may be a liquid or hydrogel reservoir, or may take some other form.
- the backing layer in these laminates which serves as the upper surface of the device, preferably functions as a primary structural element of the "patch" and provides the device with much of its flexibility.
- the material selected for the backing layer is preferably substantially impermeable to the active agent(s) and any other materials that are present.
- other pharmaceutical delivery systems can be employed.
- liposomes, emulsions, and microemulsions/nanoemulsions are well known examples of delivery vehicles that may be used to protect and deliver pharmaceutically active compounds.
- Certain organic solvents such as dimethyl sulfoxide also can be employed, although usually at the cost of greater toxicity.
- the combined formulation comprises the GABA receptor activating ligand(s) and/or the PAM(s) at a dosage (unit dosage) than would be provided if the GABA receptor activating ligand and/or the PAM were used alone.
- GABA receptor activating ligand is present at less than about 90%, or less than about 80%, or less than about 70%, or less than about 60%, or less than about 50%), or less than about 40%, or less than about 40%, or less than about 30%, or less than about 10%), or less than about 5% of the GABA receptor activating ligand required to promote the replication, and/or survival, and/or function of beta cells when the GABA receptor activating ligand is used alone.
- the PAM(s) are provided at a subtherapeutic dosage.
- the recommended/approved dosage of alprazolam (immediate release tablets) for treatment of panic disorder is an initial dose of 0.5 mg orally 3 times a day with a maintenance dose of 1 to 10 mg/day in divided doses and a mean dose of 5 to 6 mg/day in divided doses.
- the recommended/approved dosage extended release alprazolam tablets is 0.5 mg to 1 mg once a day and the maintenance dose is 1 to 10 mg once a day with a mean dose of 3 to 6 mg once a day.
- the recommended/approved dosage of alprazolam (immediate release tablets) for treatment of adult depression is an initial dose of 0.5 mg orally 3 times a day which is increased to an average effective dose of 3 mg orally daily in divided doses.
- Geriatric doses for anxiety are provided at an initial dose of 0.25 mg orally 2 to 3 times a day in elderly or debilitated patients and a daily dose greater than 2 mg meets the Beers criteria as a medication that is potentially inappropriate for use in older adults.
- a subtherapeutic dosage is typically less than the lowest recommended/approved unit dosage form, e.g., in the case of alprazolam less than 0.25 mg as a unit dosage form and a total of less than 0.5 mg daily in a treatment method.
- the subtherapeutic dosage is less than 90% or less than about 80%, or less than about 70%, or less than about 60%, or less than about 50%, or less than about 40%, or less than about 30%, or less than about 20%, or less than about 10% of this
- the actual dosage amount of the BAB A receptor activating ligand and PAM administered to a subject can be determined by physical and physiological factors such as body weight, severity of condition, previous or concurrent therapeutic interventions, idiopathy of the patient and on the route of administration. Depending upon the dosage and the route of administration, the number of administrations of a preferred dosage and/or an effective amount may vary according to the response of the subject. The practitioner responsible for administration will, in any event, determine the concentration of active ingredient(s) in a composition and appropriate dose(s) for the individual subject.
- kits are provided for the practice of the methods described herein.
- the kits comprise a container containing a GABA activating ligand, and a container containing positive allosteric modulator of the GABA A receptor as described herein.
- the kit comprises GABA and alprazolam.
- the GABA receptor activating ligand(s) and PAM(s) can be provided in unit dosage formulation(s) (e.g., tablet, caplet, patch, etc.) and/or may be optionally combined with one or more pharmaceutically acceptable excipients.
- the GABA receptor activating ligand(s) and PAM(s) can be provided in separate containers.
- the GABA receptor activating ligand(s) and PAM(s) can be provided in the same container. In certain embodiments the GABA receptor activating ligand(s) and PAM(s) can be provided in the same container as a combined formulation.
- kits optionally include labeling and/or instructional materials providing directions (i.e., protocols) for the practice of the methods of this invention.
- Certain labeling or instructional materials describe the use of a combination of GABA receptor activating ligand(s) and PAM(s) to promote the replication, and/or survival, and/or function of beta cells in mammal (e.g., a mammal receiving an islet cell transplant).
- the labeling or instructional materials may also, optionally, teach preferred dosages/therapeutic regiment, counter indications and the like.
- instructional materials typically comprise written or printed materials they are not limited to such. Any medium capable of storing such instructions and communicating them to an end user is contemplated by this invention. Such media include, but are not limited to electronic storage media (e.g., magnetic discs, tapes, cartridges, chips), optical media (e.g., CD ROM), and the like. Such media may include addresses to internet sites that provide such instructional materials.
- electronic storage media e.g., magnetic discs, tapes, cartridges, chips
- optical media e.g., CD ROM
- Such media may include addresses to internet sites that provide such instructional materials.
- Alprazolam is widely prescribed for the treatment of anxiety and panic disorders. After its introduction in 1981 it rapidly became a blockbuster drug, with over 50 million
- GABA is safe for human consumption. GABA is sold over the counter as a nutraceutical. We observed that GABA treatment for 26 weeks did not significantly alter the total numbers of splenic mononuclear cells or percentages of CD4+, CD8+, T and B lymphocytes (Tian et al. (2004) J. Immunol. 173(8): 5298-5304), nor did it desensitize autoreactive T cells to GABA-mediated inhibition (Tian et al. (2004) J. Immunol. 173(8): 5298-5304; Tian (2011) Autoimmunity, 44: 465-470).
- GABAA-RS and GABAB-RS are GABAA-RS and GABAB-RS.
- GABA-Rs There are two different types of GABA-Rs; GABAA-RS and GABAB-RS.
- Immune cells primarily express GABAA-RS (Tian et al. (1999) J. Neuroimmunol. 96(1): 21- 28; Tian et al. (2004) J. Immunol. 173(8): 5298-5304; Bhat (2010) Proc. Natl. Acad. Sci. USA, 107(6): 2580-2585; Bjurstom et al. (2008) J. Neuroimmunol. 205: 44-50) while B- cells express both GABAA-RS and GABAB-RS (Ligon et al. (1997) Diabetologia, 50(4): 764-773; Tian et al. (2013) Diabetes, 62(11): 3760-3765; Braun et al. (2010) Diabetes, 59(7): 1694-2701; Gu et al. (1993) Life Sci. 52(8): 687-694; Brice et
- GABAA-RS are pentamers of different subunits that form fast-acting chloride channels.
- GABAB-RS are heterodimers of just two subunits, but their properties can be altered by other cellular proteins (Schwenk et al. (2010) Nature, 465(7295): 231-235).
- GABAB-RS form a slow-acting G-protein coupled receptor (Bettler et al. (2004) Physiol. Rev. 84(3):
- GABAA-RS and GABAB-RS are quite different (a chloride channel vs. a G- protein coupled receptor).
- Our focus in this example is on GABAA-RS because they have the capability to simultaneously inhibit autoimmune responses and promote ⁇ -cell replication and survival.
- GABAA-R subunits There are 19 different GABAA-R subunits: six types of a subunits, three different ⁇ subunits, three y's, as well as a ⁇ , ⁇ , ⁇ , and ⁇ subunit, plus three nonclassical p subunits. Five of the subunits combine in different ways to form GABAA channels that usually consist of two a's, two P's, and one of the other subunit types (see schematic diagram in Figure 1). GABAA-RS with different subunit combinations have different pharmacological properties and specific agonists and antagonists (Olsen and Tobin (1990) FASEB J. 4(5): 1469-1480; Luddens et al. (1995) Neuropharmacology, 34(3): 245-254).
- Benzodiazepines do not bind to the GABA-binding site, but rather elsewhere on GABAA-RS (the "BZD" site in diagram). While they cannot open the chloride channel, they act as positive allosteric modulators that increase in CI- conductance when GABA is bound to the receptor. Unlike GABA, which has little or no ability to pass through the blood-brain barrier, benzodiazepines can pass through the blood-brain barrier and enhance the action of GABA produced by CNS neurons. Different benzodiazepines preferentially bind to different GABAA-RS with different subunit compositions (subtypes).
- Alprazolam benzodiazepine alprazolam
- XANAX® benzodiazepine alprazolam
- Alprazolam is widely prescribed for the treatment of anxiety and panic disorders. After its introduction in 1981 it rapidly became a blockbuster drug, with over 50 million prescriptions. When used as directed, it is safe for long term use (see FDA approved labeling at
- Alprazolam promotes human islet cell proliferation in vitro.
- alprazolam may enhance the actions of endogenously produced islet GABA.
- Alprazolam is prescribed in extended release tablets that deliver 0.5-6.0 mg/day and its concentration is usually in a range of 10-100 ng/ml in the serum of persons receiving the drug therapeutically (Jones et al. (2007) Therap. Drug Monitor. 29(2): 248- 360; Fraser and Bryan (1991) J. Analyt. Toxicol, 15(2): 63-65).
- alprazolam promoted human islet cell proliferation by about 123% compared to cultures with no alprazolam (Fig. 2).
- Alprazolam and GABA act synergistically to promote human islet cell
- Combined alprazolam GABA act synergistically to inhibit ⁇ -cell autoimmunity.
- An additional advantage of administering GABA along with alprazolam is the potential for synergistically inhibiting autoreactive T cells and promoting Tregs.
- the level of GABA in the blood is very low (there is very little GAD outside the CNS to produce GABA, and GABA has a very short half-life in circulation).
- alprazolam alone should not have much effect on immune cells, but in combination they may act synergistically to inhibit inflammation and promote Tregs, perhaps using reduced dosages of each drug. While studies of alprazolam+GABA' s effects on immune responses are of great interest, they are outside the scope of this study, which focused on human B-cell replication. Translatability of alprazolam for enhancing B-cell replication and survival in humans. Alprazolam does not cause immune suppression or increase susceptibility to infections in humans (see the alprazolam fact sheet at
- Alprazolam's main side effect is sleepiness.
- alprazolam may have enhanced the actions of neuronally produced GABA on infiltrating immune cells. In this case, it may have similar beneficial actions on islet-infiltrating immune cells.
- the only other reports of alprazolam affecting the immune system were 1) one group reported that alprazolam inhibited the proliferative responses of mouse lymphocytes and reduced the production of IL-2 by T cells and TNF by macrophages (Chang et al. (1991) Int. J.
- alprazolam in direct contrast, another group reported that alprazolam enhanced mitogen-induced lymphocyte proliferation and NK cell activity (Fride et al. (1990) Life Sci., 47(26): 2409- 2420).
- Alprazolam should not be confused with other benzodiazepines such as diazepam (valium) and lorazepam that have adverse side effects on the immune system and the CNS.
- alprazolam binds significantly to the protein previously known as the "peripheral benzodiazepine receptor", which is now known to be a translocator protein (TSPO) on the outer mitochondrial membrane (Papadopoulos et al. (2006) Trend. Pharmacol. Sci. 27(8): 402-409), and is a secondary binding site for diazepam.
- TSPO translocator protein
- alprazolam significantly reduced HbAlc in patients with poor glucose control (Lustman et al. (1995) Diabetes Care, 18(8): 1133-1139).
- Our pilot studies show that a modest level of alprazolam (alone) had a fairly robust effect on human islet cell proliferation in vitro (Fig. 2).
- the combination of alprazolam and GABA had a synergistic effect on human islet cell proliferation such that a ten-fold higher level of GABA (alone) was needed to achieve a similar proliferative effect (Fig. 3). This suggests that in combination with GABA, lower levels of alprazolam may promote ⁇ -cell replication and survival.
- alprazolam need not get through the blood brain barrier, lower dosages of alprazolam than those used for anxiolytic (anti -anxiety) effects may be effective for modulating B-cell GABAA-Rs in the periphery.
- GABAA-RS are clustered together on neuronal synapses while extra- synaptic GABA-Rs have a diffuse distribution (Craig et al. (1994) Proc. Natl. Acad. Sci. USA, 91(26): 12373-12377).
- clustered GABAA-RS have a 3-4 fold higher ECso for GAB A and deactivate faster compared to diffuse extra-synaptic GABA-Rs because of a decrease in affinity for GAB A (Chen et al. (2000) Proc. Natl. Acad. Sci. USA, 97(21): 11557-11562). It is thought that protein-protein interactions between clustered GABA-Rs affect the binding site or channel activation (Chen et al. (2000) Proc. Natl. Acad. Sci. USA, 97(21): 11557-11562). Without being bound to a particular theory, we believe it is likely that GABAA-RS on B-cells are diffuse and more sensitive to GABA and allosteric modulation.
- alprazolam+GABA combination therapy is believed to excel due to its ability to simultaneously inhibit autoreactive T cells and promote Tregs.
- anxiolytic doses of alprazolam were able to decrease HbAlc in diabetic patients (Lustman et al. (1995) Diabetes Care, 18(8): 1133-1139).
- anxiolytic doses of alprazolam are required to promote B-cell survival and replication, the benefits of short-term alprazolam treatment outweigh the side effects (primarily sleepiness).
- alprazolam treatment would be limited to the period shortly after islet implantation in order to reduce B-cell loss due to hypoxia and stress.
- alprazolam treatment may be given short-term in combination with GABA and, for example, anti-CD3— this might synergistically inhibit autoimmunity and induce Tregs, allowing C-peptide levels to be preserved for a longer time period than after treatment with anti-CD3 alone.
- Clonazepam (MW315): dissolved in ethanol at 50 mM. Methods:
- 3 H-thymi dine incorporation assay INS-1 cells at lxl0 5 /well were treated in triplicate with indicated concentrations of individual compounds and cultured in 10% FCS RPMI164 medium in the presence of 0.3 ⁇ of 3H-thymidine for 48 hours (an optimal time period). The cells were harvested and the levels of 3 H-thymidine uptake in individual wells were measured by beta-counter.
- MTT assay INS-1 cells at lxl0 5 /well were treated in quadruplicate with the indicated compounds in 10% FCS RPMI164 medium (phenol -free) for 44 hours. The cells were exposed to 20 ml of MTT (20 mg/ml) for 4 hours and the supernatants of cultured cells were removed. The resulting products were dissolved in 100 ml DMSO and measured at absorbance of 540/650 nm in microplate reader.
- INS-1 cell proliferation in vitro we tested the effect of midazolam and clonazepam on GABA-induced INS-1 cell proliferation in vitro.
- treatment with GABA at 1-0.1 mM stimulated INS-1 cell proliferation in vitro.
- Treatment with midazolam at 10 "7 or 3xl0 "8 M enhanced GABA-induced INS-1 cell proliferation.
- treatment with GABA at 0.03-0.01 mM failed to induce INS-1 cell proliferation treatment with both GABA at such low doses and midazolam at 10 "7 or 3xl0 "8 M significantly enhanced INS-1 cell proliferation.
- TSPO translocator protein (18 kDa)
- TSPO translocator protein
- AP325 (MW 310): soluble in DMSO at 50 mM;
- AP3 (MW 276.33): dissolved in DMSO at 50 mM.
- 3 H-thymi dine incorporation assay INS-1 cells at lxl0 5 /well were treated in triplicate with indicated concentrations of individual compounds and cultured in 10% FCS RPMI164 medium in the presence of 0.3 uCi/well of 3 H-thymidine for 48 hours (an optimal time period). The cells were harvested and the levels of 3 H-thymidine uptake in individual wells were measured by beta-counter.
- MTT assay _ INS-1 cells at lxl0 5 /well were treated in quadruplicate with the indicated compounds in 10% FCS RPMI164 medium (phenol -free) for 44 hours.
- the cells were exposed to 20 ml of MTT (20 mg/ml) for 4 hours and the supernatants of cultured cells were removed. The resulting products were dissolved in 100 ml DMSO and measured at absorbance of 540/650 nm in a microplate reader. Results:
- Treatment with AP325 or AP3 (alone) does not stimulate the proliferation of INS-1 cells in vitro.
- Treatment with AP325 enhances GABA-stimulated INS-1 cell proliferation in vitro.
- AP325 and AP3 can enhance GABA-induced INS-1 cell proliferation in vitro.
- a key goal of type 1 diabetes (TID) research is to develop treatments to safely promote human ⁇ -cell replication. It has recently become appreciated that activation of ⁇ -aminobutyric acid receptors (GABA-Rs) on ⁇ -cells can promote their survival and replication.
- GABA-Rs ⁇ -aminobutyric acid receptors
- a number of positive allosteric modulators (PAMs) that enhance GABA's actions on neuronal GAB A A -Rs are in clinical use. Repurposing these GABA A -R PAMs to help treat diabetes is theoretically appealing because of their safety and potential to enhance the ability of GABA, secreted from ⁇ -cells, or exogenously administered, to promote ⁇ -cell replication and survival.
- GABAA-R PAMS can enhance INS-1 ⁇ -cell replication and that this is amplified by exogenous GABA application.
- a GABAA-R PAM promoted human islet cell replication in vitro. This effect was ablated by a GABAA-R antagonist, suggesting that GABA released from ⁇ -cells can have an autocrine pro-mitotic effect that can be enhanced by a PAM.
- the combination of a PAM and low levels of exogenous GABA had increased ability to promote human ⁇ -cell replication.
- a goal of TID research is to discover approaches that can safely promote ⁇ - cell replication.
- few agents have been found that can enhance human ⁇ -cell replication.
- Rodent and human ⁇ -cells have been long known to express GABA-Rs, both GABAA-RS and GABA B -Rs (Braun et al. (GABA) (2010) Diabetes, 59: 1694-1701), but only recently has it been shown that their activation can promote ⁇ -cell survival, replication and mass (Ligon et al. (2007) Diabetologia, 50: 764-773; Soltani et al. (201 ⁇ ) Proc. Natl. Acad. Sci. USA, 108: 11692-11697; T n et al. (2013) Diabetes, 62: 3760-3765;
- GABA A -R PAMs enhance the action of GABA. They do not bind to the GABA-binding site, but rather elsewhere on GABA A -Rs and while they cannot open the GABAA-R chloride channel, they increase in Cl ⁇ conductance when GABA is bound to the receptor.
- BBB-permeable GABAA-R PAMS such as the benzodiazepines, were developed to enhance the action of GABA secreted by CNS neurons in order to treat CNS disorders such as seizures, insomnia, and anxiety. Theoretically, these PAMs could be repurposed to enhance the action of GABA that is released within the islets to promote ⁇ -cell mitogenesis.
- Alprazolam, midazolam, clonazepam, PK11195, and bicuculline were purchased from Sigma-Aldrich, and AP3 was provided by Algiax Pharmaceuticals GmbH. Stock solutions of alprazolam (10 mM in DMSO), midazolam (6.25 mM in water), clonazepam (50 mM in ETOH), or AP3 (50 mM in DMSO) were diluted into media to the indicated concentration.
- Program and islets (50-75 IEQ/well) were treated with the indicated dosage of GAB A, together with, or without, the indicated PAM for 4 days in the presence of 3 H thymidine (0.2 ⁇ ).
- INS-1 cells express benzodiazepine-binding GABAA-R subunits.
- GABA can enhance INS-1 cell proliferation (Soltani et al. (2011) Proc. Natl. Acad. Sci. USA, 108: 11692-11697), but it is unknown whether INS-1 cells express
- GABA A -subunits that are sensitive to benzodiazepines We tested INS-1 cell RNA for the expression of the GAB AA-R subunits that confer sensitivity to benzodiazepines (ai, a 2 , a 3 , and a 5 ) using qRT-PCR. We detected ai, a 3 , and a 5 transcripts as well as Bl, ⁇ , ⁇ 2, ⁇ 3 subunits (data not shown), indicating that INS-1 cells may express GABAA-RS that are sensitive to benzodiazepines.
- INS-1 cells have relatively low ability to synthesize GABA.
- INS-1 cells express GAD and secrete GABA which can act in an autocrine fashion. Whether INS-1 cells also synthesize GABA is unknown. We therefore tested GAD enzymatic activity in INS-1 cells. We found that GAD activity in INS-1 cells was considerably less than that in human islets, which in turn was less than that in mouse brain (Fig. 9, panel A). Nonetheless, GAD activity in INS-1 cells was consistently about 2-fold greater than that of negative control 293T cells, suggesting that they are capable of producing a low level of GABA that may act in an autocrine manner.
- GABAA-RS PAMs promote INS-1 proliferation in vitro.
- GABAA-R PAMs can potentiate GABA-induced ⁇ -cell proliferation.
- Some benzodiazepines bind to the mitochondrial translocator protein (TSPO) which was previously referred to as a "peripheral benzodiazepine receptor". Alprazolam does not bind to TSPO (Schmoutz et al. (2014) Behav. Brain. Res. 271 : 269-276).
- INS-1 cells were cultured with the TSPO inhibitor PK11195 and stimulated with 0.3 mM GABA in the presence of midazolam or clonazepam.
- Treatment with PK1119 did not affect the ability of GABA and the tested benzodiazepines to enhance INS-1 cell replication (Fig. 9, panel H), indicating that this effect was not mediated through TSPO.
- Alprazolam enhances the ability of islet-produced GABA to promote human islet cell replication.
- alprazolam acted in conjunction with GABA secreted from the islet B-cells to increase B-cell replication beyond its basal level.
- GABAA-R antagonist bicuculline which competitively inhibits GABA binding to GABAA-RS (Johnston (2013) Br. J.
- GABA GABA to promote human islet cell replication in vitro. Human islets were treated with, or without, different concentrations of GABA in the presence or absence of 100 nM
- alprazolam greatly reduces the amount of GABA needed to induce B-cell proliferation.
- GABA-R activation can protect B-cells from apoptosis and promote their replication (Ligon et al. (2007) Diabetologia, 50: 764-773; Soltani et al. (2011) Proc. Natl. Acad. Sci. USA, 108: 11692-11697; T n et al. (2013) Diabetes, 62: 3760-3765;
- alprazolam and exogenous GABA had a greater ability to promote human B-cell replication, and achieved a level of B-cell replication similar to that of GABA at ten-fold higher levels.
- the vast majority of islet cells that underwent replication in our assay are likely to be B-cells because immunohistological analyses have shown that GABA increases human B-cell replication but has no effect on a-cell replication (Purwana et al. (2014) Diabetes, 63(12): 4197-4205), and our unpublished observations), and islet ⁇ and PP cells are not known to express GABA-Rs.
- a short-term PAM treatment may help reduce B-cell loss due to hypoxia and stress following islet transplantation, as suggested by the ability of GABA treatment to improve B-cell survival in human islet xenografts (Tian et al. (2013) Diabetes, 62: 3760-3765; Purwana et al. (2014) Diabetes, 63(12): 4197-4205).
- immune cells also express GABA-Rs and their activation can inhibit proinflammatory immune responses such that GABA treatment ameliorates disease in mouse models of T1D, experimental autoimmune encephalomyelitis, rheumatoid arthritis and T2D (Soltani et al. (2011) Proc. Natl. Acad. Sci. USA, 108: 11692- 11697; Prud'hart et al. (2103) Transplantation, 96(7): 616-623; Tian et al. (2014) Diabetes, 63 : 3128-3134; Mendu et al. (201 1) Mol. Immunol. 48: 399-407; Bhat et al.
- peripherally-restricted GABAA-R PAMs, or subclinical doses of BBB-permeable PAMs, in combination with low dose GAB A may avoid CNS effects and promote B-cell mass/function as well as help control autoreactive T cell responses.
Abstract
Description
Claims
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2016338916A AU2016338916B2 (en) | 2015-10-14 | 2016-10-12 | Enhancing beta cell replication and/or survival |
US15/761,795 US20180235916A1 (en) | 2015-10-14 | 2016-10-12 | Enhancing beta cell replication and/or survival |
CA3043292A CA3043292A1 (en) | 2016-01-18 | 2016-10-12 | Enhancing beta cell replication and/or survival |
KR1020187011125A KR20180054796A (en) | 2015-10-14 | 2016-10-12 | Improvement of beta cell replication and / or survival |
EP16856063.9A EP3362069A4 (en) | 2015-10-14 | 2016-10-12 | Enhancing beta cell replication and/or survival |
JP2018519274A JP6957455B2 (en) | 2015-10-14 | 2016-10-12 | Increased beta cell replication and / or survival |
CN201680060060.XA CN108697712A (en) | 2015-10-14 | 2016-10-12 | Enhance β cellular replications and/or survival |
JP2021164809A JP2022008902A (en) | 2015-10-14 | 2021-10-06 | Enhancing replication and/or survival of beta cells |
AU2022202004A AU2022202004A1 (en) | 2015-10-14 | 2022-03-23 | Enhancing beta cell replication and/or survival |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562241566P | 2015-10-14 | 2015-10-14 | |
US62/241,566 | 2015-10-14 | ||
US201662279908P | 2016-01-18 | 2016-01-18 | |
US62/279,908 | 2016-01-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2017066240A1 true WO2017066240A1 (en) | 2017-04-20 |
Family
ID=58518528
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2016/056528 WO2017066240A1 (en) | 2015-10-14 | 2016-10-12 | Enhancing beta cell replication and/or survival |
Country Status (7)
Country | Link |
---|---|
US (1) | US20180235916A1 (en) |
EP (1) | EP3362069A4 (en) |
JP (2) | JP6957455B2 (en) |
KR (1) | KR20180054796A (en) |
CN (1) | CN108697712A (en) |
AU (2) | AU2016338916B2 (en) |
WO (1) | WO2017066240A1 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018236955A1 (en) * | 2017-06-23 | 2018-12-27 | The Regents Of The University Of California | Enhancing gaba's ability to modulate immune responses |
US10940156B2 (en) | 2016-03-08 | 2021-03-09 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
EP3866777A4 (en) * | 2018-10-18 | 2022-07-20 | The Regents of the University of California | Combination therapies for treatment of inflammatory diseases |
US11426417B2 (en) | 2012-01-23 | 2022-08-30 | Sage Therapeutics, Inc. | Neuroactive steroid formulations and methods of treating CNS disorders |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK2925327T3 (en) | 2012-11-30 | 2024-03-25 | Univ California | Allopregnanolone for the treatment, reduction or relief of symptoms of postpartum depression |
CN115361944A (en) * | 2020-01-10 | 2022-11-18 | 均衡生物制药私人有限责任公司 | Treatment of neurological disorders with avermectins |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20130251671A1 (en) * | 2010-09-28 | 2013-09-26 | The Regents Of The University Of California | Gaba agonists in the treatment of disorders associated with metabolic syndrome and gaba combinations in treatment or prophylaxis of type i diabetes |
US20150240235A1 (en) * | 2012-09-27 | 2015-08-27 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for producing a population of pancreatic beta-cells |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU3503300A (en) * | 1999-02-24 | 2000-09-14 | Regents Of The University Of California, The | Gaba receptors mediate inhibition of t cell responses |
CA2941782C (en) * | 2014-03-18 | 2022-08-23 | Algiax Pharmaceuticals Gmbh | 2-cyano-3-cyclopropyl-3-hydroxy-n-aryl-thioacrylamide derivatives |
-
2016
- 2016-10-12 AU AU2016338916A patent/AU2016338916B2/en active Active
- 2016-10-12 EP EP16856063.9A patent/EP3362069A4/en active Pending
- 2016-10-12 KR KR1020187011125A patent/KR20180054796A/en not_active Application Discontinuation
- 2016-10-12 US US15/761,795 patent/US20180235916A1/en active Pending
- 2016-10-12 CN CN201680060060.XA patent/CN108697712A/en active Pending
- 2016-10-12 WO PCT/US2016/056528 patent/WO2017066240A1/en active Application Filing
- 2016-10-12 JP JP2018519274A patent/JP6957455B2/en active Active
-
2021
- 2021-10-06 JP JP2021164809A patent/JP2022008902A/en active Pending
-
2022
- 2022-03-23 AU AU2022202004A patent/AU2022202004A1/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20130251671A1 (en) * | 2010-09-28 | 2013-09-26 | The Regents Of The University Of California | Gaba agonists in the treatment of disorders associated with metabolic syndrome and gaba combinations in treatment or prophylaxis of type i diabetes |
US20150240235A1 (en) * | 2012-09-27 | 2015-08-27 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for producing a population of pancreatic beta-cells |
Non-Patent Citations (5)
Title |
---|
"GABAA receptor positive allosteric modulator", WIKIPEDIA, 28 September 2015 (2015-09-28), XP055377033, Retrieved from the Internet <URL:https://en.wikipedia.org/w/index.php)?title=GABAA_receptor_positive_allosteric-modulator&oldid-683189212> * |
CRISWELL, H. E. ET AL.: "Effect of zolpidem on gamma-aminobutyric acid (GABA)-induced inhibition predicts the interaction of ethanol with GABA on individual neurons in several rat brain regions", JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, vol. 273, no. 1, 1995, pages 526 - 536, XP055377035 * |
MENDELSON, W. B. ET AL.: "Effects of muscimol and flurazepam on the sleep EEG in the rat", LIFE SCIENCES, vol. 47, no. 19, 1990, pages PL 99 - PL 101, XP025550929 * |
METCALF, B, R. ET AL.: "Discrimination of gamma-hydroxybutyrate and ethanol administered separately and as a mixture in rats", PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, vol. 70, no. 1, 2001, pages 31 - 41, XP055377030 * |
VAN TILBURG, T. J.: "Evaluation of the discriminative stimulus effects of 1, 4-butanediol, a metabolic precursor of gammahydroxybutyrate", MASTER' S THESES, 2008, XP055377036 * |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11426417B2 (en) | 2012-01-23 | 2022-08-30 | Sage Therapeutics, Inc. | Neuroactive steroid formulations and methods of treating CNS disorders |
US10940156B2 (en) | 2016-03-08 | 2021-03-09 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
US11554125B2 (en) | 2016-03-08 | 2023-01-17 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
WO2018236955A1 (en) * | 2017-06-23 | 2018-12-27 | The Regents Of The University Of California | Enhancing gaba's ability to modulate immune responses |
JP2020524702A (en) * | 2017-06-23 | 2020-08-20 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | Enhancing GABA's ability to regulate the immune response |
EP3642206A4 (en) * | 2017-06-23 | 2021-04-07 | The Regents of The University of California | Enhancing gaba's ability to modulate immune responses |
EP3866777A4 (en) * | 2018-10-18 | 2022-07-20 | The Regents of the University of California | Combination therapies for treatment of inflammatory diseases |
Also Published As
Publication number | Publication date |
---|---|
EP3362069A1 (en) | 2018-08-22 |
AU2016338916B2 (en) | 2021-12-23 |
CN108697712A (en) | 2018-10-23 |
JP2022008902A (en) | 2022-01-14 |
KR20180054796A (en) | 2018-05-24 |
JP2018530581A (en) | 2018-10-18 |
AU2016338916A1 (en) | 2018-05-31 |
EP3362069A4 (en) | 2019-10-02 |
US20180235916A1 (en) | 2018-08-23 |
JP6957455B2 (en) | 2021-11-02 |
AU2022202004A1 (en) | 2022-04-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2016338916B2 (en) | Enhancing beta cell replication and/or survival | |
AU2018201436B2 (en) | New therapeutic approaches for treating Parkinson's disease | |
GB2448224A (en) | Combination of a nicotine receptor agonist and a dopaminergic agent with reduced side effects in the treatment of Parkinson's disease and the like | |
US20200138830A1 (en) | Enhancing gaba's ability to modulate immune responses | |
WO2009153291A1 (en) | Combination of pilocarpin and methimazol for treating charcot-marietooth disease and related disorders | |
NO335735B1 (en) | A pharmaceutical composition comprising moxonidine as a selective I1-imidazoline receptor agonist and eprosartan as angiotensin II receptor blockers and their use in the manufacture of a medicament for the treatment of hypertension | |
EP2744493A1 (en) | Combinations of a 5-ht4 receptor agonist and a pde4 inhibitor for use in therapy | |
Koltunowska et al. | The influence of ionotropic and metabotropic glutamate receptor ligands on anxiety-like effect of amphetamine withdrawal in rats | |
TW202214242A (en) | Use of chiauranib or derivatives thereof in manufacture of medicament for prevention and/or treatment of non-hodgkin's lymphoma | |
US10533012B2 (en) | (R)-pirlindole and its pharmaceutically acceptable salts for use in medicine | |
US9814729B2 (en) | Nerve agent antidotes | |
Wei et al. | Agmatine inhibits morphine-induced locomotion sensitization and morphine-induced changes in striatal dopamine and metabolites in rats | |
CA3043292A1 (en) | Enhancing beta cell replication and/or survival | |
US20240115588A1 (en) | Use of proteasome inhibitors in the treatment of coronavirus infections | |
US7998973B2 (en) | Tivozanib and temsirolimus in combination | |
EP3182967B1 (en) | Dexmecamylamine for use in the treatment of hyperhidrosis | |
Poshyvak et al. | Axitinib displays antiseizure activity on pentylenetetrazol–induced kindling mode | |
KR20240021760A (en) | Treatment methods for Alzheimer's disease | |
WO2013154513A1 (en) | The use of 5-ht7 receptor antagonists including some atypical antipsychotics as antipruritic agents | |
Liu | Identification and Characterization of Antidiabetic and Antihypertensive Agents from Three Traditional Herbal Medicines | |
Hesselink et al. | Repositioning Problems of Clonidine as Topical Formulation in Neuropathic Pain | |
CN112915190A (en) | Pharmaceutical composition and application thereof in preparing medicine for preventing and treating tumors | |
AU2004233564A1 (en) | Combination of desoxypeganine and mecamylamine for the treatment of alcohol abuse | |
Guacil | Alteplase Thrombolytic Actilyse® Activase® |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 16856063 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 15761795 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2018519274 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 20187011125 Country of ref document: KR Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2016338916 Country of ref document: AU Date of ref document: 20161012 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 3043292 Country of ref document: CA |